A carregar...
First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
SIMPLE SUMMARY: There is a growing body of literature demonstrating high cancer drug costs relative to the benefits provided to patients treated on a large scale. We examined the cost-effectiveness of atezolizumab–bevacizumab for the first-line treatment of patients with unresectable hepatocellular...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7956424/ https://ncbi.nlm.nih.gov/pubmed/33668100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13050931 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|